ISO/FDIS 19015:2025(en)

ISO/TC 249/WG 1

Secretariat: SAC

Date: 2025-02-0503-10

Traditional Chinese medicine — *Glycyrrhiza uralensis* and *Glycyrrhiza glabra* seeds and seedlings

FDIS stage

(https://standards.iteh.ai) **Document Preview**

ISO/FDIS 19015

ISO/DISFDIS 19015:2025(en)

© ISO 20242025

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office CP 401 • Ch. de Blandonnet 8 CH-1214 Vernier, Geneva Phone: + 41 22 749 01 11 EmailE-mail: copyright@iso.org

Website: www.iso.org

Published in Switzerland

iTeh Standards (https://standards.iteh.ai) Document Preview

ISO/FDIS 19015

ISO/FDIS 19015:2025(en)

Contents

rorew	/oratv	
Introd	luctionv	
1	Scope	
2	Normative references	
3	Terms and definitions	
4	Descriptions3	
5 5.1	Requirements and recommendations9 General characteristics	
5.2 5.3	Glycyrrhiza uralensis and Glycyrrhiza glabra seeds	
6	Sampling	
6.1 6.2	Seed sampling	
7	Test methods10	
7.1	External test10	
7.2	Purity	
7.3	Maturity10	
7.4	Seed viability11	
7.5	Germination percentage11	
7.6	Seed moisture content11	
7.7	1 000-seed mass11	
7.8	Nematode testing11	
7.9	Seedling mass11	
7.10	Hibernaculum diameter11	
7.11	Root length11	
B https	://standards_iteh.ai/catalog/standards/iso/cc145e29-76b7-4339-a943-be22787c9acd/iso-fdis-1901 Test report	
9	Packaging, storage and transportation12	
10	Marking12	
Biblio	graphy13	

ISO/DISFDIS 19015:2025(en)

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO document should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html. This document was prepared by Technical Committee ISO/TC 249, Traditional.chinese.medicine.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html. https://www.iso.org/members.html. https://wwww.iso.org/members.html. <a href="https://www.iso.org/members.h

ISO/FDIS 19015:2025(en)

Introduction

Liquorice is one of the most frequently used medicinal plants and has been used as a traditional Chinese medicine (TCM) for more than 4 000 years. It is widely used in medicine, food and cosmetics industry worldwide. It is rich in triterpenoids and flavonoids, such as ammonium glycyrrhizinate, glycyrrhizin, liquiritin, liquiritigenin, isoliquiritigenin, isoliquiritin, glabridin, and has antitumor, antimicrobial, antiviral, antiinflammatory, immunoregulatory, antioxidant and other effects. It is included in the Pharmacopoeia of the People's Republic of China, European Pharmacopoeia, Japanese Pharmacopoeia, Korean Pharmacopoeia and United States Pharmacopoeia. It is also used as a sweetener, an antioxidant, an antibacterial agent, a foaming agent and a flavour enhancer. Meanwhile, it is a food additive approved by the European Union, the United States, China and other countries (or regions). Glabridin is recognized as a safe whitening agent because it has a significant inhibitory effect on tyrosinase activity and has low toxicity to melanocytes. Between 2019 and 2021, a total of 119 countries (or regions) engaged in international trade of liquorice products. 3 countries (or regions) only exported and 60 countries (or regions) only imported liquorice products. 56 countries (or regions) both exported and imported liquorice products. It is ranked no. 1 in the priority list of single herbal medicines for developing standards in ISO/TR 23975;2025.

Three original plants, *Glycyrrhiza uralensis* Fisch., *Glycyrrhiza glabra* L. and *Glycyrrhiza inflata* Bat. are defined as liquorice in the Pharmacopoeia of the People's Republic of China, European Pharmacopoeia and Korean Pharmacopoeia. Due to high-intensity anthropogenic activities that cause habitat destruction and uncontrolled exploitation, liquorice resources have become increasingly limited. With the development of artificial cultivation technology geared towards meeting the growing market demands, cultivated varieties of liquorice have become the primary source of liquorice products. At present, only *G. uralensis* and *G. glabra* have realized the large-scale cultivation. High quality seeds and seedlings are the assurance of the efficacy and safety of clinical drug use. In the production of *G. uralensis* and *G. glabra*, the problems of confusion, heterozygosity and uneven quality of seeds and seedlings often occur. At present, an international standard for *G. uralensis* and *G. glabra* seeds and seedlings is absent. Therefore, it is urgent to formulate an international standard for *G. uralensis* and *G. glabra* seeds and seedlings. It is the requirement of the global trade and production. It can ensure the higher productivity and better product quality from origin and benefit seed or seedling trading, plantation and the related pharmaceutical industry.

iTeh Standards (https://standards.iteh.ai) Document Preview

ISO/FDIS 19015